PERTH, Australia – Australia's largest venture capital firm, Brandon Capital Partners, has raised AU$210 million (US$147 million) for a new medical research fund that will invest in early stage discoveries linked to Medical Research Commercialization Fund (MRCF) members, a network of more than 50 medical research institutes and hospitals across Australia and New Zealand.
PERTH, Australia – Drug safety advisories around the globe are often inconsistent, and Australia's Therapeutic Goods Administration (TGA) is one of the most inconsistent compared to its peers, according to a review of drug regulators in Australia, Canada, the U.K. and the U.S. over the last decade.
PERTH, Australia – Australia's largest venture capital firm, Brandon Capital Partners, has raised AU$210 million (US$147 million) for a new medical research fund that will invest in early stage discoveries linked to Medical Research Commercialization Fund (MRCF) members, a network of more than 50 medical research institutes and hospitals across Australia and New Zealand.
PERTH, Australia – Drug safety advisories around the globe are often inconsistent, and Australia's Therapeutic Goods Administration (TGA) is one of the most inconsistent compared to its peers, according to a review of drug regulators in Australia, Canada, the U.K. and the U.S. over the last decade.
PERTH, Australia – Que Oncology Inc., a joint venture between Emory University and the University of Queensland, has kicked off its phase II trials in the U.S. and Australia for its lead therapy to treat hot flashes in breast cancer patients.
PERTH, Australia – Que Oncology Inc., a joint venture between Emory University and the University of Queensland, has kicked off its phase II trials in the U.S. and Australia for its lead therapy to treat hot flashes in breast cancer patients.
